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Skeletal muscle differentiation involves myoblast
alignment, elongation, and fusion into multinucleate
myotubes, together with the induction of regulatory and
structural muscle-specific genes. Here we show that two
phosphatidylinositol 3-kinase inhibitors, LY294002 and
wortmannin, blocked an essential step in the differenti-
ation of two skeletal muscle cell models. Both inhibitors
abolished the capacity of L6E9 myoblasts to form myo-
tubes, without affecting myoblast proliferation, elonga-
tion, or alignment. Myogenic events like the induction of
myogenin and of glucose carrier GLUT4 were also
blocked and myoblasts could not exit the cell cycle, as
measured by the lack of mRNA induction of p21 cyclin-
dependent kinase inhibitor. Overexpresssion ofMyoD in
10T1/2 cells was not sufficient to bypass the myogenic
differentiation blockade by LY294002. Upon serumwith-
drawal, 10T1/2-MyoD cells formedmyotubes and showed
increased levels of myogenin and p21. In contrast,
LY294002-treated cells exhibited none of these myogenic
characteristics and maintained high levels of Id, a neg-
ative regulator of myogenesis. These data indicate that
whereas phosphatidylinositol 3-kinase is not indispen-
sable for cell proliferation or in the initial events of
myoblast differentiation, i.e. elongation and alignment,
it appears to be essential for terminal differentiation of
muscle cells.
The development of skeletal muscle is a multistep process
that involves the determination of pluripotential mesodermal
cells to give rise to myoblasts, withdrawal of the myoblasts
from the cell cycle and differentiation into muscle cells, and
finally growth and maturation of skeletal muscle fibers (1).
At the molecular level, myogenic commitment and muscle-
specific gene expression involve the skeletal muscle-specific
helix-loop-helix (bHLH)1 MyoD family of proteins, which in-
cludes MyoD, myogenin, myf-5, and MRF4, and the myocyte
enhancer-binding factor 2 (MEF2). Each of the MyoD-family
proteins and also MEF2A indiscriminately direct non-muscle
cells into the myogenic lineage by auto- and cross-activating
bHLH genes (2–4). The myogenic activity of the MyoD family
proteins requires heterodimerization with ubiquitously ex-
pressed E2a gene products to form functional transcription
complexes (5, 6). The DNA binding activity of MyoD family
proteins is attenuated by Id, which forms complexes with E2a
gene products in proliferating cells and is down-regulated when
they are induced to differentiate (7, 8).
The decision to differentiate into myotubes is influenced
negatively by several factors. Treatment of myoblasts with
fetal bovine serum, basic fibroblast growth factor 2, or trans-
forming growth factor b1 is known to inhibit differentiation of
myoblasts (9, 10). Myogenesis is also regulated negatively by
oncogenes such as c-myc, c-jun, c-fos, H-ras, and E1a (11–16).
There is very little information regarding the signaling that
is triggered in the myoblast upon serum withdrawal which
leads to the induction of the MyoD family gene expression and
to muscle differentiation. Myogenic differentiation seems to
depend on the activation of integrins present on the plasma
membrane of myoblasts (17, 18), suggesting the operation of an
“outside-in” biochemical pathway in which integrin is the up-
stream molecular species. Interactions of insulin-like growth
factor (IGF)-I and -II with their receptors are also positive
regulators of skeletal muscle differentiation (19). However, the
intracellular events occurring between receptor activation and
terminal differentiation remain obscure.
Phosphatidylinositol 3-kinases (PI 3-kinases) are involved in
receptor signal transduction via tyrosine kinase receptors and
in protein trafficking in eukaryotic cells. Multiple forms of PI
3-kinases have been reported. A well characterized group of PI
3-kinases are heterodimers composed of a regulatory p85 sub-
unit and a catalytic p110 subunit (20, 21). In contrast, the
recently cloned PI 3-kinase g (22) does not couple to p85 and is
activated by Gbg subunits (23, 24). A third group of PI 3-ki-
nases includes the VPS34 gene product from Saccharomyces
cerevisiae (25, 26) and its human homolog (27). The Vps34p
only phosphorylates the 39 position of PI and is required for
vacuolar protein sorting (25). This last group of PI 3-kinases
associate with a 150–160-kDa protein, which in S. cerevisiae is
a serine/threonine kinase essential for Vps34p activity (28). All
PI 3-kinase isoforms so far described are potently inhibited in
the nanomolar or low micromolar range by two structurally
unrelated membrane permeant reagents: wortmannin (for re-
view, see Ref. 29) and LY294002 (30).
While much information has been accumulated on the role of
PI 3-kinase activities in tyrosine kinase receptor signal trans-
duction or vesicle trafficking, little is known about the possible
role of PI 3-kinases in cell differentiation. In this regard, it has
been observed that PI 3-kinase might be involved in neurite
outgrowth of PC12 cells (31). In a previous report, we showed
that PI 3-kinase activity and insulin-stimulated glucose trans-
port in L6E9 muscle cells were inhibited in a dose-response
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manner by a 1-h treatment with wortmannin (32). Here we
show that chronic treatment with LY294002 or wortmannin
blocked morphological and biochemical changes associated
with L6E9 myoblast terminal differentiation and that this in-
hibition is not bypassed by the overexpression of MyoD in
10T1/2 cells. Data presented here implicate PI 3-kinase as an
essential positive regulator of terminal differentiation of skel-
etal muscle cells.
EXPERIMENTAL PROCEDURES
Materials—Wortmannin was kindly given by Dr. Trevor Payne (San-
doz, Basel) and LY294002 was from BioMol Research Laboratories
(Plymouth Meeting, PA). L6E9 rat skeletal muscle cell line was kindly
provided by Dr. B. Nadal-Ginard (Harvard University). 10T1/2 cells
transfected with MyoD were obtained from Dr. Vicente Andrés (St.
Elizabeth’s Medical Center, Boston, MA).
The polyclonal antibody OSCRXwas raised against the C terminus of
GLUT4 (33). The polyclonal antibodies against rat p85 PI 3-kinase were
from Upstate Biotechnology Inc. (Lake Placid, NY). A rabbit polyclonal
antibody against b1-integrin was kindly given by Dr. Carles Enrich
(University of Barcelona) (34). cDNAs encoding for myogenin and p21
were kindly given by Dr. Eric Olson (University of Texas, Houston, TX)
and David Beach (Cold Spring Harbor Laboratory, Cold Spring Harbor,
NY), respectively. cDNA for Id was obtained from Dr. Harold Weintraub
(Fred Hutchinson Cancer Research Center, Seattle, WA).
Cell Culture—Rat skeletal muscle L6E9 myoblasts were grown in
monolayer culture in Dulbecco’s modified Eagle’s medium containing
10% (v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotics (10,000
units/ml penicillin G and 10 mg/ml streptomycin). Confluent myoblasts
were differentiated by lowering FBS to a final concentration of 2% (v/v).
10T1/2 fibroblasts transfected with MyoD were grown as L6E9 cells in
the presence of 0.5 mg/ml geneticin, and differentiated in Dulbecco’s
modified Eagle’s medium containing 5% (v/v) horse serum with antibi-
otics and geneticin.
To analyze the effect of PI 3-kinase inhibitors on cell differentiation,
confluent cells were washed twice in phosphate-buffered saline solution
(PBS) and low serummedium was added without or with LY294002 (10,
20, or 50 mM) or wortmannin (1 mM). Both inhibitors were initially
dissolved in dimethyl sulfoxide and in all experimental series, control
cells were treated with the corresponding volumes of dimethyl sulfox-
ide. Due to the instability of wortmannin in aqueous solutions (31),
after washing twice in PBS, medium from cells treated with wortman-
nin and untreated controls was replaced every 5 h during the differen-
tiation period (2–4 days).
RNA Isolation and Northern Blot Analysis—Total RNA from cells
was extracted using the phenol/chloroform method (35). All samples
had a 260/280 absorbance ratio above 1.7.
After quantification, total RNA (30 mg) was denatured at 65 °C in the
presence of formamide, formaldehyde, and ethidium bromide (36). RNA
was separated on a 1.8% agarose/formaldehyde gel, blotted on Hybond
N filters, and processed as previously reported (33). The blots were then
hybridized to the corresponding probes overnight at 42 °C in 50% form-
amide, 5 3 Denhardt’s, 0.1% SDS, 5 3 SSPE, 10% dextran sulfate, and
200 mg/ml denatured salmon sperm DNA. The mouse cDNA probe for
myogenin was a 1,100-base pair EcoRI fragment, the mouse cDNA
probe for Id was a 900-bp SmaI fragment, and the human cDNA probe
for p21 was a 600-bp NotI fragment. The cDNA probes were labeled
with [a-32P]dCTP by random oligonucleotide priming. The probes were
included at 1–2 3 106 cpm/ml.
Preparation of Membrane Fractions from Muscle Cells—Cells were
homogenized by 20 strokes with a Dounce A homogenizer in 10 volumes
of ice-cold buffer containing 20 mM Hepes, 250 mM sucrose, 2 mM EGTA,
5 mM NaN3, 0.2 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, and
1 mM pepstatin, pH 7.4. Homogenates were centrifuged at 760 3 g for 10
min at 4 °C. The supernatants were then centrifuged at 200,000 3 g for
90 min at 4 °C to obtain the membrane fractions. The membrane pellets
were resuspended in homogenization buffer and repeatedly passed
through a 25-gauge needle before storage at 220 °C. Proteins were
measured by the method of Bradford (37) using g-globulin as a standard
and 30 mg of total membranes from each experimental series were
submitted to SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Immunoprecipitation of p85 Subunit of PI 3-Kinase—Immunopre-
cipitation from solubilized cells was performed as described previously
(32). The immunopellets were resuspended in SDS-PAGE sample buffer
under reduction conditions and electrophoresed.
Electrophoresis and Immunoblotting of Membranes—SDS-PAGE
was performed following Laemmli (38). Proteins were transferred to
Immobilon in buffer consisting of 20%methanol, 200 mM glycine, 25 mM
Tris, pH 8.3. Following transfer, the filters were blocked with 5% nonfat
dry milk and 0.02% NaN3 in PBS for 1 h at 37 °C and then incubated
overnight at 4 °C with antibodies against GLUT4 (1:400), b1-integrin
(1:1000), and p85 (1:1000) in PBS containing 1% nonfat dry milk and
0.02% sodium azide. b1-Integrin was detected using
125I-protein A for
3 h at room temperature. GLUT4 and p85 were detected by ECL
chemiluminiscence system.
RESULTS
LY29004 and Wortmannin Inhibit the Fusion of L6E9 Myo-
blasts into Myotubes—L6E9 skeletal muscle myoblasts were
grown in a proliferating medium containing 10% FBS (Fig. 1A)
and when confluent, myoblasts were incubated in a 2% FBS-
containing medium (differentiation medium). Under these con-
ditions, myoblasts elongated and aligned with each other dur-
ing the first 24 h and multinucleate myotube formation was
observed during the following 72 h (Fig. 1, B and D, day 2 and
4, respectively). When the differentiation medium was added
together with the PI 3-kinase inhibitor LY294002 (10, 20, or 50
mM), L6E9 myoblasts aligned as did the untreated control myo-
blasts. However, no fusion into myotubes was observed during
the 4 days required for full differentiation. Fig. 1 shows myo-
blasts treated with 10 mM LY294002 in differentiation medium
for 2 and 4 days (C and E, respectively). Identical effects were
observed at 20 or 50 mM LY294002 (data not shown).
Myoblasts fusion was also blocked when confluent myoblasts
were allowed to differentiate in a medium containing 1 mM
wortmannin, another inhibitor of PI 3-kinases. It has been
shown that wortmannin is highly unstable in aqueous solu-
tions (29). For this, our dose-response studies were limited to
LY294002; in experiments using 1 mM wortmannin, after wash-
ing twice in PBS, culture medium from control and treated cells
was replaced by fresh medium with dimethyl sulfoxide or with
wortmannin, respectively, every 5 h throughout the differenti-
ation period (2–4 days). Under these conditions, control myo-
blasts aligned with each other during the first 24 h in differ-
FIG. 1. LY294002 inhibits myotube formation in L6E9 muscle
cells. L6E9 myoblasts were grown to confluence in a 10% FBS-contain-
ing medium (A) and then allowed to differentiate by serum deprivation
(2% FBS-containing medium) in the absence (B and D) or presence (C
and E) of 10 mM LY294002. Cells were photographed after 2 days (B and
C) or 4 days (D and E) in low serum medium. Magnification: 125 3.
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entiation medium (not shown) and formed multinucleate
myotubes after 2 days (Fig. 2B). In contrast, myoblasts in
differentiation medium with 1 mM wortmannin aligned with
each other but did not fuse into myotubes (Fig. 2C). Identical
effects were observed after a 4-day treatment with wortmannin
(data not shown).
LY29004 and Wortmannin Inhibit Myogenin mRNA Induc-
tion Associated with Differentiation—It has been described that
the lack of the bHLH muscle regulatory factor myogenin re-
duces myotube formation in vivo (39, 40), indicating that myo-
genin has a unique function in the transition from a deter-
mined myoblast to a fully differentiated myotube. Based on
this, we next analyzed the effect of PI 3-kinase inhibitors on
myogenin mRNA levels during the differentiation period. As
shown in Fig. 3A, LY294002 blocked the induction of myogenin
mRNA which is normally observed on differentiation days 2
and 4. The maximal effect of LY294002 was observed at a
concentration of 10 mM. Similar results were obtained when
1 mM wortmannin was added to the differentiation medium
and myogenin mRNA levels were determined at days 2 and 4
(Fig. 3B).
LY29004 and Wortmannin Inhibit mRNA Induction of
p21cdk Inhibitor Associated with Differentiation—An early
event during the muscle differentiation process is the exit of
myoblasts from the cell cycle. A marker of this event is the
induction of the mRNA expression of p21cdk inhibitor. Indeed,
it is known that ectopic expression of p21 in growing myoblasts
is sufficient to inhibit cell cycle progression (41). As expected, 2
days after serum deprivation, L6E9 myotubes showed in-
creased mRNA levels of p21 compared to proliferating cells
(Fig. 4). In contrast, the absence of p21 mRNA induction in
LY294002-treated cells (10 mM or 20 mM), strongly suggests that
PI 3-kinase activity may be essential to signal the cell cycle exit
in differentiating muscle cells.
LY29004 and Wortmannin Inhibit the Muscle-specific Induc-
tion of the Glucose Transporter GLUT4 in L6E9 Cells—To
determine whether the blockade of multinucleate myotube for-
mation by LY294002 and wortmannin was associated with the
inhibition of differentiation at the biochemical level, we ana-
lyzed the expression of GLUT4, a skeletal muscle marker, in
cells allowed to differentiate in the absence or presence of
LY294002 or wortmannin.
After 4 days in differentiation medium, the total membrane
content of GLUT4 was increased by 2.42 6 0.46-fold (n 5 3) in
myotubes compared to myoblasts (Fig. 5,Mt versus Mb). When
50 mM LY294002 or 1 mM wortmannin were present during the
4 days of differentiation, little or no induction in GLUT4 ex-
pression was observed (Fig. 5, LY orW versus Mb). In contrast,
PI 3-kinase inhibitors did not affect the expression of two
non-muscle-specific proteins: the structural plasma membrane
component b1-integrin and the p85 regulatory subunit of PI
3-kinase. As shown in Fig. 5, the expression level of these
proteins was unaffected after 4 days in differentiation medium
either in the absence or presence of PI 3-kinase inhibitors.
LY294002 Inhibits Myotube Formation in 10T1/2 Cells Sta-
bly Transfected with MyoD—Multinucleate myotube formation
together with muscle-specific gene onset can be induced by
overexpression of MyoD or the other members of myogenic
bHLH transcription factors (myogenin, MyoD, myf5, and
MRF4); each of these four myogenic factors indiscriminately
FIG. 2. Wortmannin inhibits myotube formation in L6E9 mus-
cle cells. L6E9 myoblasts were grown to confluence in a 10% FBS-
containing medium (A) and then allowed to differentiate by serum
deprivation (2% FBS) during 2 days in the absence (B) or presence (C)
of 1 mM wortmannin. Magnification: 320 3.
FIG. 3. LY294002 and wortmannin inhibit the induction of
myogenin mRNA in L6E9 muscle cells. Confluent L6E9 myoblasts
(Mb) were allowed to differentiate in low serum medium for 2 or 4 days
in the absence or presence of LY294002 (A: 10, 20 or 50 mM) or 1 mM
wortmannin (B). Total RNA was obtained from the different experimen-
tal groups and 30 mg of RNA was laid on gels. After blotting, myogenin
mRNA was detected by hybridization with a 1,100-base pair EcoRI
fragment as a cDNA probe. Representative autoradiograms after 2 days
of exposure, from three to five experiments, are shown. The integrity
and relative amounts of RNA in each sample were checked by ethidium
bromide staining (rRNA).
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directs non-muscle cells into the myogenic lineage by auto- and
cross-activating bHLH genes (2, 3). Consistent with these ob-
servations, 10T1/2 cells stably transfected with MyoD (10T1/2-
MyoD) were able to fuse to each other upon serum withdrawal.
Large multinucleate myotubes were observed from differenti-
ation day 2 up to day 4 (Fig. 6, A and C). In contrast, when
confluent 10T1/2-MyoD cells were serum-deprived in the pres-
ence of 50 mM LY294002, cells progressively adopted an elon-
gated shape but were unable to form myotubes (Fig. 6, B and
D), indicating that the overexpression of MyoD could not by-
pass the blockade of skeletal muscle differentiation by the PI
3-kinase inhibitor LY294002.
LY294002 Blocks Biochemical Differentiation in 10T1/2-
MyoD Cells—We next analyzed whether LY294002 inhibition
of 10T1/2-MyoD myotube formation was accompanied by a
blockade of biochemical differentiation, as we had previously
observed in L6E9 cells. To this end, we first determined the
mRNA levels of myogenin in undifferentiated cells and in cells
allowed to differentiate in the absence or presence of 50 mM
LY294002 for 2 days. As seen in Fig. 7A, myogenin mRNA
levels were induced after serum withdrawal in 10T1/2-MyoD
cells and this induction was blocked in the presence of the PI
3-kinase inhibitor LY294002.
As observed for L6E9 cells and consistent with the observa-
tion that MyoD induces p21cdk inhibitor expression in vitro (41,
42), serum-deprived 10T1/2-MyoD cells showed increased
mRNA levels of p21 compared to proliferating cells (Fig. 7B).
However, as observed in L6E9 cells, p21 mRNA induction was
blocked by LY294002, indicating that the PI 3-kinase inhibitor
impaired the cell cycle exit.
We next determined the effect of LY294002 on the mRNA
levels of Id. It is known that undifferentiated 10T1/2-MyoD
cells express high levels of this dominant negative bHLH pro-
tein, which inactivates MyoD by heterodimerization with E2a
gene products and which is down-regulated during myogenesis
(7, 8). As expected, Id mRNA level in 10T1/2-MyoD cells was
decreased after 2 days in differentiation medium (Fig. 7C). In
contrast, when LY294002 was added together with the differ-
entiation medium, Id mRNA level was not down-regulated.
This absence of Id down-regulation could explain at least in
FIG. 4. LY294002 inhibits the induction of p21cdk inhibitor
mRNA levels in L6E9 muscle cells. Confluent L6E9 myoblasts (Mb)
were allowed to differentiate in low serum medium for 2 days in the
absence or presence of LY294002 (10 or 20 mM). Total RNA was obtained
from the different experimental groups and 30 mg of RNA was laid on
gels. After blotting, p21 mRNA was detected by hybridization with a
600-base pair NotI fragment as a cDNA probe. A representative auto-
radiogram after 2 weeks of exposure, from three separate experiments,
is shown. The integrity and relative amounts of RNA in each sample
were checked by ethidium bromide staining (rRNA).
FIG. 5. LY294002 and wortmannin inhibit the induction of the
skeletal muscle marker GLUT4 protein content in L6E9 muscle
cells. Confluent L6E9 myoblasts were allowed to differentiate for 4
days in the absence or presence of 50 mM LY294002 or 1 mM wortman-
nin. Total membrane proteins from confluent myoblasts (Mb) and from
cells in differentiation medium without (Mt) or with PI 3-kinase inhib-
itors (LY, 50 mM LY294002; W, 1 mM wortmannin) were obtained.
GLUT4 glucose transporter and b1-integrin content was analyzed by
immunoblotting 30 mg of total membrane proteins from the different
experimental groups. PI 3-kinase p85-subunit was analyzed by immu-
noprecipitating 2.5 mg of solubilized proteins from the different exper-
imental groups with anti-p85 polyclonal antibody and then immuno-
blotting with the same antibody. Representative autoradiograms from
three separate experiments of each group are shown.
FIG. 6. LY294002 inhibits myotube formation in 10T1/2 cells
transformed with MyoD. 10T1/2-MyoD cells were grown to conflu-
ence in a 10% FBS-containing medium and then allowed to differentiate
following serum deprivation (5% horse serum containing medium) in
the absence (A and C) or presence (B and D) of 50 mM LY294002. Cells
were photographed after 2 days (A and B) or 4 days (C and D) in low
serum medium. Magnification: 215 3.
FIG. 7. LY294002 inhibits the induction of myogenin and p21
mRNA and the down-regulation of Id mRNA in serum-deprived
10T1/2-MyoD cells. Confluent 10T1/2-MyoD cells (day 0) were allowed
to differentiate in low serum medium for 2 days in the absence or
presence of 50 mM LY294002. Total RNA was obtained from the differ-
ent experimental groups and 30 mg of RNA were laid on gels. After
blotting, myogenin was detected by a 1,100-bp EcoRI fragment as a
cDNA probe (A); p21 mRNA was detected by hybridization with a
600-bp NotI fragment (B) and Id was detected by a 900-bp SmaI frag-
ment (C). Representative autoradiograms after 1–2 days of exposure,
from three separate experiments, are shown. The integrity and relative
amounts of RNA in each sample were checked by ethidium bromide
staining (rRNA).
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part the inability of MyoD to induce cell fusion and myogenin
and p21 mRNA expression in LY294002-treated cells.
DISCUSSION
In this study we have shown that two structurally different
inhibitors of phosphatidylinositol 3-kinase, i.e. LY294002 and
wortmannin, blocked both the morphological and the biochem-
ical differentiation of two skeletal muscle models, L6E9 myo-
blasts and 10T1/2 cells stably transfected with MyoD
(10T1/2-MyoD).
In a previous report, we showed that PI 3-kinase activity and
insulin-stimulated glucose transport in L6E9 muscle cells were
inhibited by 1 h treatment with wortmannin. The inhibition of
insulin action was dose-dependent with an ED50 around 10–20
nM (32). Here we show that chronic treatment with LY294002
or wortmannin blocked both the morphological and the bio-
chemical differentiation of L6E9 cells. PI 3-kinase inhibitors
did not interfere with myoblast proliferation at the doses used
(data not shown) and they did not cause any alteration in the
elongation or alignment of myoblast observed during the first
24 h after serum deprivation. However, whereas untreated
cells began to fuse a few hours after alignment, wortmannin- or
LY294002-treated cells remained aligned but did not fuse into
myotubes. PI 3-kinase also appears to be essential for signaling
leading to the onset of muscle-specific gene expression. Thus,
both wortmannin and LY294002 blocked the induction of myo-
genin mRNA levels and the exit from the cell cycle as measured
by the lack of p21 mRNA expression. The induction of the
skeletal muscle marker GLUT4 was also impaired without
changes in the expression of two non-muscle-specific proteins:
b1-integrin, an integral plasma membrane protein and the p85
regulatory subunit of PI 3-kinase. This suggests that PI 3-ki-
nase inhibitors only affected differentiation-associated events.
Similar results were obtained when 10T1/2-MyoD cells were
allowed to differentiate in the presence of the phosphatidyl-
inositol 3-kinase inhibitor LY294002: cells elongated but they
were unable to fuse. Upon serum deprivation, untreated 10T1/
2-MyoD cells formed multinucleate myotubes and induced the
expression of myogenin and p21 mRNAs. In contrast, none of
these myogenic characteristics was observed when 10T1/2-
MyoD myoblasts were allowed to differentiate in the presence
of LY294002.
Our results seem to indicate that PI 3-kinase inhibitors
prevented the activation of other muscle regulatory factors
such as myf5 or MyoD, already expressed during the myoblast
phenotype (43). Indeed, this was the case in 10T1/2-MyoD cells
where MyoD overexpression in undifferentiated cells did not
bypass the inhibitory action of LY294002. It has been reported
that the activity of muscle regulatory factors can be prevented
by increasing the levels of Id protein or by silencing their
transcriptional activity as a result of phosphorylation catalyzed
by different kinases (15, 16). In this study, we focused our
attention on the dominant negative bHLH protein Id, which is
normally down-regulated after serum deprivation but which
remained expressed at high levels in LY294002-treated 10T1/
2-MyoD cells. This blockade of Id down-regulation could ex-
plain, at least in part, the inability of overexpressed MyoD to
induce differentiation.
In all, our data implicate PI 3-kinase at an early step in the
terminal differentiation of muscle cells and rule it out as an
essential component in the control of proliferation of myoblast
cells or the initial morphological changes associated with dif-
ferentiation such as alignment and elongation of myoblasts. A
schematic summary of our results is presented in Fig. 8.
PI 3-kinases have been associated with many signal trans-
duction pathways, indicating that this family of enzymes plays
a variety of roles in response to different stimuli. Here we
present results that strongly implicate PI 3-kinase activity in
myogenesis. However, the precise myogenic mechanism(s) that
are blocked by the PI 3-kinase inhibitors remain to be defined.
At the moment, there is very scarce information regarding the
signaling pathways by which the microenvironment influences
myogenesis. Among the non-exclusive positive regulators of
myogenesis that have been described are the insulin growth
factors IGF-I, IGF-II, and their specific receptors, and also, the
occupation of the extracellular matrix receptors integrins. The
following observations allow us to postulate the involvement of
PI 3-kinase(s) in myogenic signaling pathways.
(i) Growth factors are generally considered to inhibit myo-
genesis (reviewed in Ref. 1). However, it has been reported that
myoblasts in low serum medium initiate the expression of
IGF-II which is secreted in significant amounts to the medium
(44). It has been proposed that the insulin-like growth factors
IGF-I and -II act in an autocrine and/or paracrine manner on
myoblasts to promote myogenic differentiation by interacting
primarily with the IGF-I receptor (45). In this regard, IGF-
binding proteins from muscle cells inhibit IGF-I-induced differ-
entiation of L6E9 myoblasts (46).
The intracellular myogenic signaling process dependent on
IGFs is poorly understood but it is known that IGF-I receptors
associate through IRS-I with the p85 regulatory subunit of PI
3-kinase. This interaction results in the activation of the en-
zyme (47, 48) and the phosphorylation of IRS-1 by the serine
FIG. 8. Model for a role of PI 3-kinase in differentiation of
muscle cells. Upon serum withdrawal, myoblasts differentiate. At the
morphological level, myoblasts initially elongate and align. A few hours
later, cells begin to fuse to each other to give rise to multinucleate
myotubes. When PI 3-kinase inhibitors are added together with the
differentiation medium and maintained throughout the differentiation
period, myoblasts are able to proceed through the first differentiation
events, i.e. elongation and alignment, but the rest of the differentiation
program appeared to be blocked: (i) Id down-regulation is inhibited and
it is known that high levels of Id inactivate MyoD; (ii) MyoD remains
inactive; (iii) myogenin gene expression is not induced and (iv) the gene
expression p21 cdk inhibitor is blocked, suggesting that myoblasts are
unable to exit the cell cycle, an essential step for full differentiation.
These events finally lead to the inability of myoblasts to fuse into
multinucleate myotubes and to express muscle-specific proteins such as
GLUT4.
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kinase activity of PI 3-kinase (49, 50). If such an association
were also essential for myogenic signaling, PI 3-kinase inhibi-
tors may block terminal differentiation at this level. On the
other hand, IGF-II receptors have also been implicated in myo-
genesis by using the IGF-II receptor-selective (Leu-27) IGF-II
analog (51) and, interestingly, wortmannin has been shown to
block exocytosis of IGF-II receptors in 3T3-L1 adipocytes (52).
(ii) Integrins seem to play an important role in mediating
signals from the extracellular matrix to influence myogenesis.
Indeed, in the presence of a monoclonal antibody which blocks
the function of the integrin b-subunit, myoblasts continue to
replicate but do not fuse or express muscle-specific markers
(17). Myotube formation is also inhibited by antibodies against
the integrin VLA-4 and its counter-receptor VCAM-1 (18). In-
terestingly, an integrin-dependent translocation of PI 3-kinase
to the cytoskeleton which involves specific interactions of p85a
with actin filaments and focal adhesion kinase has been re-
cently demonstrated in thrombin-stimulated platelets (53).
Moreover, integrin and platelet-derived growth factor receptor
regulate the association of PI 3-kinase with focal adhesion
kinase in NIH3T3 cells (54). An analogous mechanism for PI
3-kinase activation via integrins in muscle cells would provide
an explanation for the effect of PI 3-kinase inhibitors on myo-
genic differentiation.
(iii) Many reports have recently proposed a role for a mam-
malian PI 3-kinase in membrane trafficking. Indeed, wortman-
nin and/or LY294002 have been shown to disrupt GLUT1 traf-
ficking in L6E9 myoblasts (32), to block exocytosis of IGF-II
receptors in 3T3-L1 adipocytes (52), and to inhibit the sorting
and transport of lysosomal enzymes (55, 56). Moreover, a mam-
malian homolog of the yeast PI 3-kinase vacuolar protein sort-
ing Vps34p has been recently cloned (27). Thus, PI 3-kinase
inhibitors could be blocking myogenesis by disrupting the in-
tracellular trafficking of proteins involved in the myogenic
signaling through IGFs and/or integrins although other regu-
latory mechanisms cannot be ruled out.
In conclusion, these data suggest that one or more PI 3-ki-
nase isoforms might be involved in the myogenic signaling
through different positive effectors. We are now attempting to
define the myogenic pathway(s) that depend on PI 3-kinase
activity and to identify the isoform(s) of PI 3-kinase involved in
myogenesis.
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